Head-to-head · WeighScore
Omada Health vs Vea Health
The verdict
Omada Health takes it — 55.6/100 to 55/100, but only just.
Omada Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Omada Health is a virtual care company offering behavior-change programs for weight health, diabetes and hypertension, distributed through employers and health plans. Vea Health is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Omada Health | Vea Health |
|---|---|---|
| WeighScore | 55.6/100 | 55/100 |
| Grade | C | C |
| Scorecard rank | #435 | #450 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Yes |
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Graded #450 · C
Strengths
- Publishes the FDA compounded-medication disclaimer
- Oral and injection protocols for both semaglutide and tirzepatide
- Claims 50-state coverage via a clinician network
- Clearly differentiated positioning (longevity, men's health, performance)
Where it loses points
- Pricing not shown until after sign-up
- Pharmacy partner not named (only 'U.S.-based pharmacy')
- LegitScript certification status not visible
- No named medical director
- 503A vs 503B designation not specified
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.